Evaluation of the 3-drug combination, Rifater, versus 4-drug therapy in the ambulatory treatment of tuberculosis in Cape Town.

Abstract

The subjective impression among clinicians that the use of Rifater was causing delayed sputum conversion and increased drug resistance was tested in a prospective study. Adults in the Cape Town municipal area with a first episode of pulmonary tuberculosis were treated either with Rifater or a regimen consisting of isoniazid, rifampicin, pyrazinamide and ethambutol. All patients who took the treatment as prescribed (67 Rifater, 39 the 4-drug regimen) converted to a negative sputum culture by the time 90 doses had been taken. The rates of inadequate compliance and of side-effects were similar in the two groups. Drug sensitivity testing of bacteria cultured from pre-treatment sputum specimens revealed an overall primary resistance rate of 4.84% in the population studied, sufficiently low to preclude any necessity for routine pre-treatment drug sensitivity testing.

• Authors: M F Macnab, P D Bohmer, J R Seager
• Journal: South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde (S Afr Med J) Vol. 84 Issue 6 Pg. 325-8 (Jun 1994) ISSN: 0256-9574 [Print] South Africa
• PMID: 7740377 (Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article)

Chemical References

• Antitubercular Agents
• Drug Combinations
• isoniazid, pyrazinamide, rifampin drug combination
• Pyrazinamide
• Ethambutol
• Isoniazid
• Rifampin
• Streptomycin

Topics

• Antitubercular Agents (therapeutic use)
• Drug Combinations
• Drug Resistance, Microbial
• Ethambutol (adverse effects, therapeutic use)
• Humans
• Isoniazid (adverse effects, therapeutic use)
• Patient Compliance
• Prospective Studies
• Pyrazinamide (adverse effects, therapeutic use)
• Rifampin (adverse effects, therapeutic use)
• Sputum (microbiology)
• Streptomycin (adverse effects, therapeutic use)
• Tuberculosis (drug therapy)